Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Early Research Calls<p><strong>Downgrades:</strong></p><ul><li><strong>Verint Systems</strong> (VRNT 44.05) downgraded to In-line from Outperform at Imperial Capital; tgt raised to $45 from $43. Firm notes that despite their decision to raise their price target by 5% to $45 from $43, based on 13x their FY18 EBTIDA estimate, they see the potential for material share price appreciation over the next year to be limited. Nonetheless, they remain constructive on the company and its long-term prospects.</li></ul><p><strong><em>Misc</em></strong></p><ul><li><strong>Dermira</strong> (DERM 35.11) initiated with a Buy at Mizuho; tgt $42. Firm notes that although the co is not yet profitable, Dermira has developed several innovative late-stage products that they believe would be attractive to potential buyers. They think that 2017 represents a slow year with respect to potential data catalysts (no data disclosures or FDA approval dates). However, Dermira intends to remain visible at a number of 2017 dermatology conferences ahead of its expected 2018 launches and may also get a boost from other M&A in the sector.</li><li><strong>Alaska Air</strong> (ALK 93.66) target lowered to $98 from $101 at Imperial Capital. Firm notes they are maintaining their FY17 estimate, while lowering their FY18 estimate to $8.05 from $8.50. Their new FY18 estimate assumes RASM increases 0.5% versus 1% previously, and CASM ex-fuel increases 1.5% versus 0.5% previously, including their estimated $20mn impact from wage increases for Virgin's employees following ratification of single labor agreements. They now estimate total realized merger synergies of $45 mln in FY18 versus $146 mln previously</li></ul></td> </tr></table>"